Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 88,664,688
  • Shares Outstanding, K 1,647,430
  • Annual Sales, $ 19,427 M
  • Annual Income, $ 4,457 M
  • 36-Month Beta 1.09
  • Price/Sales 4.60
  • Price/Cash Flow 17.65
  • Price/Book 6.14

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.32 +2.01%
on 05/18/17
56.83 -4.29%
on 05/01/17
+0.45 (+0.83%)
since 04/25/17
3-Month
52.51 +3.58%
on 04/06/17
58.54 -7.09%
on 03/10/17
-2.05 (-3.63%)
since 02/24/17
52-Week
46.01 +18.21%
on 01/26/17
77.12 -29.47%
on 07/15/16
-16.30 (-23.06%)
since 05/25/16

Most Recent Stories

More News
Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer

Bristol-Myers Squibb Company (BMY) announced that the FDA has accepted and granted a priority review designation to the supplemental Biologics License Application for the label expansion of Opdivo to patients...

AGLE : 4.43 (-6.74%)
VVUS : 1.12 (+1.82%)
MEIP : 1.97 (+17.96%)
BMY : 54.39 (+1.06%)
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb's Application for Opdivo (nivolumab) in Previously Treated Hepatocellular Carcinoma

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) that seeks to...

BMY : 54.39 (+1.06%)
Blog Coverage: Bristol-Myers Squibs Received EMA Validation of Sprycel for the Treatment in Children with Chronic Myelogenous Leukemia

Upcoming AWS Coverage on GW Pharmaceuticals Post-Earnings Results

GWPH : 108.02 (+1.61%)
BMY : 54.39 (+1.06%)
Lupus Nephritis Market Global Industry Trends, Share, Size, Growth and 2030 Forecasts Report - MarketReportsOnline

PUNE, India, May 22, 2017 /PRNewswire/ --

AUPH : 6.59 (-4.77%)
RHHBY : 34.3700 (+0.44%)
GSK : 42.57 (-0.88%)
BMY : 54.39 (+1.06%)
Lupus Nephritis Market Global Industry Trends, Share, Size, Growth and 2030 Forecasts Report - MarketReportsOnline

The report "Global Lupus Nephritis Market: Industry Analysis & Outlook (2021-2030)" analyses the development of this market, with focus on the U.S, Europe and Japan markets. The major trends, growth drivers...

AUPH : 6.59 (-4.77%)
RHHBY : 34.3700 (+0.44%)
GSK : 42.57 (-0.88%)
BMY : 54.39 (+1.06%)
Hepatitis Therapeutics Market to Reach $25.8 Billion by 2025 - Key Players are Gilead, Merck, Johnson & Johnson, Bristol-Myers Squibb Company & AbbVie - Research and Markets

Research and Markets has announced the addition of the "Hepatitis Therapeutics Market Analysis By Disease Type (Hepatitis A, B, C) By Region (North America, Europe, Asia Pacific, Latin America,...

JNJ : 127.53 (+0.02%)
MRK : 65.04 (+0.17%)
BMY : 54.39 (+1.06%)
New Research Reports for Britol-Myers, Pricline & Phillips 66

New Research Reports for Britol-Myers, Pricline & Phillips 66

PCLN : 1,860.43 (+0.63%)
NWL : 53.28 (+0.89%)
PSX : 77.42 (-1.10%)
PCG : 67.29 (+1.60%)
ADSK : 113.89 (+1.25%)
BMY : 54.39 (+1.06%)
Merck KGaA (MKGAF) Q1 Earnings Fall Y/Y, Revenues Increase

Merck KGaA (MKGAF) reported first-quarter 2017 earnings of $1.28 per American Depositary Share, 14.7% lower than the year-ago figure of $1.50.

RHHBY : 34.3700 (+0.44%)
PFE : 32.16 (+0.34%)
MKGAF : 116.8700 (-3.24%)
BMY : 54.39 (+1.06%)
European Medicines Agency Validates Application for Bristol-Myers Squibb's Sprycel (dasatinib) in Children with Chronic Myelogenous Leukemia

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Medicines Agency (EMA) validated its grouped Type II variation/Extension of Application for Sprycel (dasatinib)...

BMY : 54.39 (+1.06%)
Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More

This week, industry bellwether J&J (JNJ) provided a look at its pharma pipeline while Shire was up on HAE data.

BAYRY : 130.9100 (-0.83%)
JNJ : 127.53 (+0.02%)
MRK : 65.04 (+0.17%)
LLY : 78.34 (+0.49%)
SHPG : 184.82 (-0.29%)
SNY : 49.03 (-0.24%)
BMY : 54.39 (+1.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain;...

See More

Support & Resistance

2nd Resistance Point 55.11
1st Resistance Point 54.75
Last Price 54.39
1st Support Level 53.86
2nd Support Level 53.33

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.